{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:34:45Z","timestamp":1783524885589,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.08.064","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:37:35Z","timestamp":1662709055000},"page":"6055-6063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells"],"prefix":"10.1016","volume":"40","author":[{"given":"Mohamed","family":"Deifallah Yousif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Felek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolya","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanette","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudaxshina","family":"Murdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatme","family":"Mawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.08.064_b0005","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cix654","article-title":"Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal disease worldwide: systematic review. clinical","volume":"65","author":"Le Doare","year":"2017","journal-title":"Infectious dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0095-5108(18)30184-2","article-title":"Group B streptococcal infections","volume":"24","author":"Baker","year":"1997","journal-title":"Clin Perinatol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.064_b0015","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"Say","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.064_b0020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jama.1991.03470080082034","article-title":"Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta","volume":"266","author":"Schwartz","year":"1991","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.064_b0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1086\/432804","article-title":"Group B streptococcal infections in elderly adults","volume":"41","author":"Edwards","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/599369","article-title":"Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990\u20132007","volume":"49","author":"Skoff","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"suppl_2","key":"10.1016\/j.vaccine.2022.08.064_b0035","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1093\/cid\/cix585","article-title":"Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses","volume":"65","author":"Seale","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"suppl_2","key":"10.1016\/j.vaccine.2022.08.064_b0040","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/cid\/cix658","article-title":"Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1473-3099(16)30055-X","article-title":"Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis","volume":"16","author":"Kwatra","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.064_b0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/00016340801908759","article-title":"Prevalence of maternal group B streptococcal colonisation in European countries","volume":"87","author":"Barcaite","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"9405","key":"10.1016\/j.vaccine.2022.08.064_b0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(03)15389-5","article-title":"Group B streptococcal disease in UK and Irish infants younger than 90 days","volume":"363","author":"Heath","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0060","doi-asserted-by":"crossref","first-page":"F90","DOI":"10.1136\/adc.2007.127464","article-title":"Group B streptococcal disease in Portuguese infants younger than 90 days","volume":"93","author":"Neto","year":"2008","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.064_b0065","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1542\/peds.2006-3246","article-title":"Group B streptococcal infections in a northern region of Italy","volume":"120","author":"Berardi","year":"2007","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.064_b0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00006454-199111000-00002","article-title":"The changing spectrum of group B streptococcal disease in infants: an eleven-year experience in a tertiary care hospital","volume":"10","author":"Yagupsky","year":"1991","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.064_b0075","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1542\/peds.2005-2481","article-title":"Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany","volume":"117","author":"Fluegge","year":"2006","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.064_b0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1440-1754.2002.00783.x","article-title":"Early-onset neonatal group B streptococcal infections in New Zealand 1998\u20131999","volume":"38","author":"Grimwood","year":"2002","journal-title":"J Paediatr Child Health"},{"issue":"12","key":"10.1016\/j.vaccine.2022.08.064_b0085","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10096-008-0565-8","article-title":"Invasive group B streptococcus (GBS) disease in Norway 1996\u20132006","volume":"27","author":"Bergseng","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0090","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/00006454-199909000-00012","article-title":"Neonatal group B streptococcal disease in Finland: a ten-year nationwide study","volume":"18","author":"Kalliola","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0095","doi-asserted-by":"crossref","first-page":"F72","DOI":"10.1136\/adc.2009.160333","article-title":"Missed opportunities for preventing GBS infections","volume":"95","author":"Vergnano","year":"2010","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"17","key":"10.1016\/j.vaccine.2022.08.064_b0100","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/jama.299.17.2056","article-title":"Epidemiology of invasive group B streptococcal disease in the United States, 1999\u20132005","volume":"299","author":"Phares","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00006454-200109000-00011","article-title":"Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation","volume":"20","author":"Davies","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1086\/382881","article-title":"Characterization of group B streptococci recovered from infants with invasive disease in England and Wales","volume":"38","author":"Weisner","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1469-0691.2004.00931.x","article-title":"Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998\u20132001","volume":"10","author":"Persson","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.064_b0120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/INF.0b013e318178d1ff","article-title":"Molecular epidemiology of invasive neonatal Streptococcus agalactiae isolates in Germany","volume":"27","author":"von Both","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.08.064_b0125","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/pathogens10121606","article-title":"Group B streptococcal colonization in african countries: prevalence, capsular serotypes, and molecular sequence types","volume":"10","author":"Shabayek","year":"2021","journal-title":"Pathogens Pathogens"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.064_b0130","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/314666","article-title":"Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women","volume":"179","author":"Lachenauer","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.08.064_b0135","doi-asserted-by":"crossref","unstructured":"N, Hirai, K, Kasahara, R, Nakano, et al. Clinical characteristics and molecular epidemiology of invasive Streptococcus agalactiae infections between 2007 and 2016 in Nara, Japan . PLoS.One. 15(10):e0240590.","DOI":"10.1371\/journal.pone.0240590"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0140","first-page":"158","article-title":"Active screening of group B streptococci with reduced penicillin susceptibility and altered serotype distribution isolated from pregnant women in kobe","volume":"66","author":"Kimura","year":"2013","journal-title":"Japan Japanese j Infectious Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.064_b0145","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpedi.1996.02170320112022","article-title":"Probable community acquisition of group B Streptococcus in an infant with late-onset disease: demonstration using field inversion gel electrophoresis","volume":"150","author":"Trager","year":"1996","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14760584.4.2.207","article-title":"Vaccination against Group B streptococcus","volume":"4","author":"Heath","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.064_b0155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clp.2005.05.005","article-title":"Prevention of neonatal sepsis","volume":"32","author":"Schrag","year":"2005","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.vaccine.2022.08.064_b0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM200007203430310","article-title":"Neonatal group B streptococcal disease:screening and prevention","volume":"343","author":"Schuchat","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.064_b0165","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/1471-0528.12371","article-title":"Are we using too many antiboitoics during -pregnancy?. BJOC: on the intestinal microbiota of infants: a systemic review","volume":"120","author":"Ledger","year":"2013","journal-title":"An Int J Obstetrics & Gynael"},{"key":"10.1016\/j.vaccine.2022.08.064_b0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/archdischild-2018-316659","article-title":"Effect of intrapartum antibiotics on the intestinal microbiota of infants. a systemic review","volume":"105","author":"Zimmermann","year":"2020","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/375536","article-title":"Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III","volume":"188","author":"Baker","year":"2003","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.064_b0180","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/315839","article-title":"Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women","volume":"182","author":"Baker","year":"2000","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2022.08.064_b0185","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/S0264-410X(03)00353-0","article-title":"Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine","volume":"21","author":"Baker","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0190","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1086\/314574","article-title":"Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib","volume":"179","author":"Baker","year":"1999","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.064_b0195","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1172\/JCI119042","article-title":"Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine","volume":"98","author":"Kasper","year":"1996","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.vaccine.2006.07.018","article-title":"Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults","volume":"25","author":"Baker","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.064_b0205","first-page":"1","article-title":"Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches","author":"Absalon","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"32","key":"10.1016\/j.vaccine.2022.08.064_b0210","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1016\/j.vaccine.2021.06.046","article-title":"Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women","volume":"39","author":"Fischer","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.064_b0215","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2010.12.014","article-title":"Sublingual mucosa: a new vaccination route for systemic and mucosal immunity","volume":"54","author":"Kweon","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2022.08.064_b0225","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jconrel.2021.03.017","article-title":"Sublingual vaccination and delivery systems","volume":"332","author":"Paris","year":"2021","journal-title":"J Controlled Release"},{"key":"10.1016\/j.vaccine.2022.08.064_b0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2014.05.060","article-title":"Buccal and sublingual vaccine delivery","volume":"190","author":"Kraan","year":"2014","journal-title":"J Controlled Release"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0235","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/14760584.2021.1951249","article-title":"Sublingual antigen delivery: a solution for needle-free HIV vaccination","volume":"20","author":"Monge","year":"2021","journal-title":"Expert rev vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.064_b0240","first-page":"e00273","volume":"4","author":"Buffi","year":"2019","journal-title":"Novel Multiplex Immunoassays for Quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human SeramSphere"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0245","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/315285","article-title":"Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate","volume":"181","author":"Paoletti","year":"2000","journal-title":"J Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2022.08.064_b0250","first-page":"3213","article-title":"Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia","volume":"29","author":"Lancaster","year":"2011","journal-title":"Ib and III Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2022.08.064_b0255","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0264-410X(00)00226-7","article-title":"Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization","volume":"19","author":"Shen","year":"2000","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2022.08.064_b0260","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJM198811033191802","article-title":"Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus","volume":"319","author":"Baker","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.064_b0265","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/595564","article-title":"Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm","volume":"199","author":"Margarit","year":"2009","journal-title":"J Infect Dis"},{"issue":"5731","key":"10.1016\/j.vaccine.2022.08.064_b0270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1126\/science.1109869","article-title":"Identification of a universal Group B streptococcus vaccine by multiple genome screen","volume":"309","author":"Maione","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1574-695X.2009.00623.x","article-title":"Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice","volume":"58","author":"Xue","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.064_b0280","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4161\/hv.8376","article-title":"A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus","volume":"5","author":"Guttormsen","year":"2009","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.064_b0285","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4161\/hv.4.5.5988","article-title":"Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells","volume":"4","author":"Guttormsen","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2022.08.064_b0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2003.tb06049.x","article-title":"The transfer of immunity from mother to child","volume":"987","author":"Hanson","year":"2003","journal-title":"Ann NYAcad Sci"},{"key":"10.1016\/j.vaccine.2022.08.064_b0295","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41598-018-20609-5","article-title":"Protective effect of group B streptococus type-III polysaccharide conjugates against maternal colonisation, ascending infection and neonatal transmission","volume":"8","author":"Chiarot","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.064_b0300","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/08923970802438441","article-title":"Secretory immunoglobulin a: well beyond immune exclusion at mucosal surfaces","volume":"31","author":"Corthesy","year":"2009","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.064_b0305","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/polym10090948","article-title":"Oral vaccine delivery for intestinal immunity-biological basis, barriers, delivery system, and m cell targeting","volume":"10","author":"Kang","year":"2018","journal-title":"Polymers (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.064_b0310","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1128\/iai.65.4.1387-1394.1997","article-title":"Comparison of the oral, rectal, and vaginal immunisation routes for induction of antibodies in rectal and genital tract secretions of women","volume":"65","author":"Kozlowski","year":"1997","journal-title":"Infec Immun"},{"key":"10.1016\/j.vaccine.2022.08.064_b0315","first-page":"1","article-title":"Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues","volume":"354","author":"Czerkinsky","year":"2012","journal-title":"Current Topics in Microbiol Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.064_b0320","doi-asserted-by":"crossref","first-page":"e1743","DOI":"10.1371\/journal.pntd.0001743","article-title":"Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in pregnancy","volume":"6","author":"Hashim","year":"2012","journal-title":"PLoSNegl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.08.064_b0325","doi-asserted-by":"crossref","unstructured":"C, Thirion-Delalande, F, Gervais, C, Fisch, et al. Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the non clinical evaluation of sublingual immunotherapy products. PLoS ONE 12(9):e0183398.","DOI":"10.1371\/journal.pone.0183398"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:17:55Z","timestamp":1759403875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":65,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22010623"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}